Hemorrhage risk from warfarin may be highest in first month | Tenn. to recontact people who got NECC drug due to new infections | Test needs only a drop of blood or saliva to find malaria
Web Version
 
 
November 28, 2012
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
SIGN UP|FORWARD|ARCHIVE

Top StorySponsored By
Hemorrhage risk from warfarin may be highest in first month
Atrial fibrillation patients who take the anticoagulant warfarin were most at risk of developing a hemorrhage during the first month of medication, according to a study of 125,195 patients in Canada. The risk for hemorrhage was as high as 15% during the first 30 days, depending on other risk factors, including hypertension and congestive heart failure. The study appeared in the Canadian Medical Association Journal. DailyRx.com (11/26)
Share: LinkedInTwitterFacebookGoogle+Email
 
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.
Advertisement
 
Science & Health
Tenn. to recontact people who got NECC drug due to new infections
The Tennessee Health Department will start recontacting more than 1,000 people exposed to the New England Compounding Center's contaminated drug methylprednisolone acetate. The move is prompted by a rise in infections distinct from the initial meningitis cases. "While these infections are not as serious as meningitis, they need to be identified and treated to prevent them from becoming a more significant health problem," Tennessee Health Commissioner Dr. John Dreyzehner said. The Tennessean (Nashville) (tiered subscription model) (11/26)
Share: LinkedInTwitterFacebookGoogle+Email
Test needs only a drop of blood or saliva to find malaria
Researchers at Aarhus University in Denmark have created a technology called Rolling Circle-Enhanced Enzyme Activity Detection that they say has high sensitivity in detecting malaria from just a single drop of blood or saliva. The test works by evaluating the mechanism of an enzyme from the Plasmodium parasite called topoisomerase I. Newstrack India/Asian News International (11/28)
Share: LinkedInTwitterFacebookGoogle+Email
Method allows aging stem cells to rejuvenate
Canadian researchers have developed a method to prompt aging stem cells to rejuvenate. The researchers created a "micro-environment" conducive to growing heart tissue from stem cells collected from elderly patients. The discovery could allow for the development of "young" patches for treating or healing damaged or diseased hearts without the fear of rejection. ZeeNews.com (India)/Indo-Asian News Service (11/28)
Share: LinkedInTwitterFacebookGoogle+Email
New app to help monitor bleeding events in hemophilia patients
Novo Nordisk has introduced its HemaGo app designed to help hemophilia patients and their caregivers monitor bleeding events and medications and manage treatment and physician appointments. Users may also keep track of infusions and details about bleeding events, the company said. MedCityNews.com (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical Research: Understanding the Methodology Toolbox
Clinical Research: Understanding the Methodology Toolbox compiles articles of evidence-based research for use as an educational resource for those involved in clinical research, healthcare professionals and trainees in transfusion medicine and other medical specialties. Now in the AABB Marketplace.
Advertisement
 
Emerging Trends
CDC study examines HIV cases in teens, young adults
More than a quarter of all new HIV cases in the U.S. in 2010 involved 13- to 24-year-olds, and 60% didn't even know they were infected, CDC researchers said. They noted that only a small percentage of high-school students and young adults have ever been tested for HIV. HealthDay News (11/27), Reuters (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
AesRx reports promising data for sickle cell disease drug
AesRx said data from a Phase I study of its sickle cell disease treatment Aes-103 showed the drug is safe and well-tolerated by patients. The data are set to be presented at a hematology meeting. Following the positive findings, AesRx has started a second trial at the NIH Clinical Center in Bethesda, Md., that will involve patients with sickle cell disease. Mass High Tech (Boston) (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
CMS penalizing hospitals to curb readmissions
Medicare is taking the maximum 1% penalty from 307 of 2,217 hospitals identified as having readmission rates that are too high as part of the Affordable Care Act's push to rein in Medicare spending increases and prevent unneeded care. Readmission penalties have captured the attention of hospitals, many of which are attempting to enhance supervision after discharge. Readmissions should be regarded as a challenge to conquer, said Dr. Harlan Krumholz of Yale-New Haven Hospital's Center for Outcomes Research and Evaluation. The New York Times (tiered subscription model) (11/26)
Share: LinkedInTwitterFacebookGoogle+Email
Agency sets comment period for stage 3 MU measures
Comments on the CMS draft recommendations for stage 3 meaningful use objectives for the EHR incentive program may be submitted until Jan. 14, according to the Office of the National Coordinator for Health IT. Health care groups and providers may give input on objectives for meaningful use, quality metrics and privacy and security measures. BeckersHospitalReview.com (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
EU expands approval of tenofovir disoproxil to include HIV-1, hep B
The European Commission approved tenofovir disoproxil fumarate, combined with other antiretroviral drugs, to treat HIV-1 in patients ages 2 to 17. The drug was also cleared for chronic hepatitis B in patients ages 12 to 17. The approval covers all 27 countries in the European Union. MedCityNews.com/News release (11/27)
Share: LinkedInTwitterFacebookGoogle+Email
Association News
"Transfusion" article reviews tool to assess bleeding severity in patients with thrombocytopenia
An article in the November issue of "Transfusion" describes a new tool -- the Bleeding Severity Measurement Scale -- for assessing bleeding severity in patients with chemotherapy-induced thrombocytopenia. The authors state that "[a]lthough various bleeding measures exist, there is no standardized and validated method of assessment of bleeding severity in patients with CIT." The scale includes three grades: Grade 0, no bleeding; Grade 1, not clinically significant bleeding; and Grade 2, clinically significant bleeding. The researchers concluded that use of the scale in clinical trials should provide valid and reliable assessments of bleeding. Continuing medical education credits are being offered for reading and successfully completing a test on the article. Read the abstract or visit the CME website.
Share: LinkedInTwitterFacebookGoogle+Email
Who's Hiring?
Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Help Desk SpecialistAABBUS - MD
Click here to view more job listings.
 
SmartQuote
The foolish man seeks happiness in the distance; the wise grows it under his feet."
-- James Oppenheim,
American poet, novelist and editor
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tom Parks
Managing Editor:  Amanda Horn
Advertising Manager:  Annette Bacchus
  M: 240.333.6604
Jobs Contact:  Jackie Basso
  P: 202.407.7871
 
 

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information